Literature DB >> 18078988

The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes.

Anik Désormeaux1, Marie Eve Moreau, Yves Lepage, Jacques Chanard, Albert Adam.   

Abstract

The combination of negatively-charged membranes and angiotensin I-converting enzyme inhibitors (ACEi) evokes hypersensitivity reactions (HSR) during hemodialysis and bradykinin (BK)-related peptides have been hypothesized as being responsible for these complications. In this study, we tested the effects of neutralizing the membrane electronegativity (zeta potential) of polyacrylonitrile AN69 membranes by coating a polyethyleneimine layer (AN69-ST membranes) over the generation of kinins induced by blood contact with synthetic membranes. We used minidialyzers with AN69 or AN69-ST membranes in an ex vivo model of plasma and we showed that plasma dialysis with AN69 membranes led to significant BK and des-Arg(9)-BK release, which was potentiated by ACEi. This kinin formation was dramatically decreased by AN69-ST membranes, even in the presence of an ACEi, and kinin recovery in the dialysates was also significantly lower with these membranes. High molecular weight kininogen and factor XII detection by immunoblotting of the protein layer coating both membranes corroborated the results: binding of these proteins and contact system activation on AN69-ST membranes were reduced. This ex vivo experimental model applied to the plasma, dialysate and dialysis membrane could be used for the characterization of the kinin-forming capacity of any biomaterial potentially used in vivo in combination with drugs which modulate the pharmacological activity of kinins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18078988      PMCID: PMC4125129          DOI: 10.1016/j.biomaterials.2007.11.019

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  21 in total

Review 1.  New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding.

Authors:  Jacques Chanard; Sylvie Lavaud; Christine Randoux; Philippe Rieu
Journal:  Nephrol Dial Transplant       Date:  2003-02       Impact factor: 5.992

2.  Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma.

Authors:  M Cyr; Y Lepage; C Blais; N Gervais; M Cugno; J L Rouleau; A Adam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-07       Impact factor: 4.733

3.  IgE antibodies to isocyanates in hemodialyzed patients.

Authors:  J Chanard; S Lavaud; F Lavaud; O Toupance; S Kochman
Journal:  ASAIO Trans       Date:  1987 Jul-Sep

4.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia.

Authors:  E V Granowitz; A A Santos; D D Poutsiaka; J G Cannon; D W Wilmore; S M Wolff; C A Dinarello
Journal:  Lancet       Date:  1991-12-07       Impact factor: 79.321

5.  Minimodule dialyser for quantitative ex vivo evaluation of membrane haemocompatibility in humans: comparison of acrylonitrile copolymer, cuprophan and polysulphone hollow fibres.

Authors:  J Mulvihill; J P Cazenave; J P Mazzucotelli; T Crost; C Collier; J L Renaux; C Pusineri
Journal:  Biomaterials       Date:  1992       Impact factor: 12.479

6.  Generation of kinins during preparation and storage of whole blood-derived platelet concentrates.

Authors:  Marie Eve Moreau; Louis Thibault; Anik Désormeaux; Miguel Chagnon; Réal Lemieux; Pierre Robillard; François Marceau; Robert W Colman; Yves Lepage; Georges-Etienne Rivard; Albert Adam
Journal:  Transfusion       Date:  2007-03       Impact factor: 3.157

7.  Anaphylactoid reactions in dialysis patients: role of ethylene-oxide.

Authors:  J Bommer; O H Wilhelms; H P Barth; H Schindele; E Ritz
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

8.  Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values.

Authors:  A Adam; A Albert; G Calay; J Closset; J Damas; P Franchimont
Journal:  Clin Chem       Date:  1985-03       Impact factor: 8.327

9.  High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine).

Authors:  M Thomas; P Valette; A L Mausset; P Déjardin
Journal:  Int J Artif Organs       Date:  2000-01       Impact factor: 1.595

10.  Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction.

Authors:  G Schulman; R Hakim; R Arias; M Silverberg; A P Kaplan; L Arbeit
Journal:  J Am Soc Nephrol       Date:  1993-03       Impact factor: 10.121

View more
  5 in total

1.  Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.

Authors:  Albert Adam; Nicolas Montpas; David Keire; Anik Désormeaux; Nancy J Brown; François Marceau; Benjamin Westenberger
Journal:  Biomaterials       Date:  2010-04-27       Impact factor: 12.479

2.  Kinin B1 receptors contributes to acute pain following minor surgery in humans.

Authors:  May Hamza; Xiao-Min Wang; Albert Adam; Jaime S Brahim; Janet S Rowan; Gilberto N Carmona; Raymond A Dionne
Journal:  Mol Pain       Date:  2010-02-13       Impact factor: 3.395

3.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

4.  Polyethyleneimine-treated polyacrylonitrile membrane hemofilter for critically ill patients receiving anticoagulant-free prolonged intermittent renal replacement therapy: a single-center, prospective, self-controlled pilot study.

Authors:  Tao Su; Qizhuang Jin; Zhongyuan Liu
Journal:  BMC Nephrol       Date:  2017-06-30       Impact factor: 2.388

5.  AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study.

Authors:  Takahiro Hirayama; Nobuyuki Nosaka; Yasumasa Okawa; Soichiro Ushio; Yoshihisa Kitamura; Toshiaki Sendo; Toyomu Ugawa; Atsunori Nakao
Journal:  J Intensive Care       Date:  2017-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.